Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Darius Sholevar

Clinical Cardiac Electrophysiology Cherry Hill, NJ Medical Doctor

NPI 1093794729 CMS profile 322186

1 Brace Rd Ste C, Cherry Hill, NJ 08034

Open in the dashboard

General payments

$28,761

512 records reported · program years 2019–2025

Research payments

$3,500

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$814,254 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Darius Sholevar of Cherry Hill, NJ is reported in the CMS Open Payments database as having received $28,761 across 512 general payments and $3,500 in research payments paid to them. Separately, studies naming them as principal investigator received $814,254 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 64th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,434 71
2024 General $3,704 88
2023 General $2,771 101
2022 General $6,092 80
2021 General $1,966 54
2020 General $1,002 36
2019 General $4,792 82
2019 Research $3,500 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Darius Sholevar
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Darius Sholevar were reported at $8,434. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Darius Sholevar Clinical Cardiac Electrophysiology median Middle half National median
2019 $4,792 $2,361 $585–$8,260 $163
2020 $1,002 $993 $247–$4,351 $114
2021 $1,966 $1,185 $326–$4,739 $132
2022 $6,092 $2,073 $554–$6,789 $149
2023 $2,771 $2,568 $759–$8,159 $160
2024 $3,704 $2,557 $703–$7,403 $164
2025 $8,434 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $10,089 95 payments
  2. Abbott Laboratories $4,357 187 payments
  3. Impulse Dynamics (USA) Inc. $3,947 24 payments
  4. Medtronic, Inc. $3,671 43 payments
  5. Medtronic Vascular, Inc. $1,954 24 payments
  6. Biosense Webster, Inc. $1,473 37 payments
  7. Medical Device Business Services, Inc. $851 4 payments
  8. Atricure, Inc. $455 5 payments
  9. Philips Electronics North America Corporation $312 23 payments
  10. Edwards Lifesciences Corporation $209 2 payments
  11. Other $1,440 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,959 480 payments
  2. Travel and Lodging $5,383 27 payments
  3. Consulting Fee $5,313 2 payments
  4. Honoraria $3,000 1 payment
  5. Education $106 2 payments
Products named General payments · program years 2019–2025
  1. FARAPULSE $5,461 6 payments
  2. Optimizer Cardiovascular $3,080 5 payments
  3. Optimizer Cardiovascular $3,038 3 payments
  4. WATCHMAN Access System $1,343 21 payments
  5. AVEIR $1,167 13 payments
  6. Carto 3 System $1,135 11 payments
  7. Confirm Rx $768 31 payments
  8. WATCHMAN FLX $749 16 payments
  9. General - Therapies $554 10 payments
  10. OPTIMIZER Cardiovascular Device $502 13 payments
  11. Other $10,887 368 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $3,500 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,009

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$348,803

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

50.1%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 191 $199,041
Xarelto Rivaroxaban Brand 87 $75,445
Multaq Dronedarone Hcl Brand 46 $59,226
Flecainide Acetate Generic 71 $4,164
Nadolol Generic 16 $2,219
Sotalol Sotalol Hcl Brand 89 $1,897
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 42 $1,191
Metoprolol Succinate Generic 68 $1,162
Dofetilide Generic 11 $894
Amiodarone Hcl Generic 46 $830

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$526,574

Medicare's payments for the services billed

Medicare patients

2,148

Average age 78

Services billed

7,099

945 women, 1,203 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 68%
Ischemic heart disease 58%
Heart failure 54%
Arthritis 49%
Diabetes 42%
Chronic kidney disease 39%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sotalol Hydrochloride
  • AltaThera Pharmaceuticals LLC $21
$21 89 —
FUROSCIX
  • SCPHARMACEUTICALS INC. $18
$18 — —
Repatha
  • Amgen Inc. $17
$17 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $16
$16 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

513 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record